London-based Cell Medica Ltd., an early stage cellular therapeutics company developing innovative cell-based treatments for infectious disease and cancer, raised £1.95m in a funding round led by Imperial Innovations Group plc., with participation from private investors.
Cell Medica has now raised a total of £4.5m in equity and convertible debt investment capital.
The proceeds will be used by Cell Medica to commercialise Virus-specific Immune Reconstitution, a cell therapy technique which protects patients with weakened immune systems against cytomegalovirus (CMV) infections, particularly after bone marrow transplants.
FinSMEs
09/10/2009